To date, three monoclonal antibodies targeting PD-1 (pembrolizumab, nivolumab, and cemiplimab) and three monoclonal antibodies targeting PD-L1 (atezolizumab, durvalumab, and avelumab) have been approved by the US Food and Drug Administration for advanced inoperable cancers in first-line, metastatic, and recurrent EC. This evidence concerns the gene CD274 and cancer.